+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Eisai

  • ID: 5357333
  • Company Profile
  • January 2021
  • 53 pages
  • Datamonitor Healthcare
  • Eisai Co
The publisher explores Eisai’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Eisai’s growth will continue to be driven by Lenvima in the mid-term, with pipeline neurology products adding significant revenues thereafter.
  • Key themes - [1] Eisai’s growth is due to approvals in additional indications for Lenvima [2] Eisai’s longer-listed products, such as Aricept, have shown to be able to retain more market share than previously expected [3] Eisai will look to gain approvals for key Alzheimer's disease pipeline products aducanumab and BAN2401 to provide long-term growth.
Model updates (5 November 2020)
  • Humira forecast adjusted higher
  • Halaven forecast adjusted higher
  • Lenvima forecast adjusted higher due to long-term growth in multiple tumor types
  • BAN2401 forecast added.
Model updates (31 January 2020)
  • Lenvima RoW forecast adjusted higher due to growth in China’s HCC market
  • Halaven RoW forecast adjusted higher due to launch in China for breast cancer.
Model updates (31 October 2019)
  • Aducanumab forecast added.
Model updates (14 August 2019)
  • Lenvima forecast adjusted higher due to revenue from additional indications
  • Aricept forecast adjusted higher due to company guidance
  • Lunesta forecast adjusted higher due to company guidance
  • Aciphex Japan forecast adjusted lower due to generics, and RoW forecast adjusted higher due to China company guidance
  • Belviq forecast adjusted lower due to RoW company guidance.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll